E. I. Khadieva, S. Yakupova, R. Abdrakipov, N. Zhuravleva
{"title":"Drug-induced lupus erythematosus","authors":"E. I. Khadieva, S. Yakupova, R. Abdrakipov, N. Zhuravleva","doi":"10.32000/2072-1757-2023-3-44-47","DOIUrl":null,"url":null,"abstract":"This article presents a clinical case in which a patient observed by neurologists with a diagnosis of neuropathy and treated with anticonvulsants and antidepressants developed new clinical manifestations and laboratory changes characteristic of systemic lupus erythematosus. A clinical version emerged that the neurological changes were the disease onset, followed by the development of the remaining clinical and laboratory symptoms (the diagnosis fully met the 2019 EULAR criteria — a score of 16 points, 10 points are sufficient to make a diagnosis). However, after a very short and low-dose therapy with methylprednisolone and hydroxychloroquine and withdrawal of anticonvulsants, there was a rapid recovery of specific antibodies and improvement of clinical symptoms, which allowed assuming drug-induced lupus erythematosus in this patient. Currently, the list of drugs that can cause this problem includes more than 100 drugs.","PeriodicalId":9821,"journal":{"name":"中国实用医药","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实用医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32000/2072-1757-2023-3-44-47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This article presents a clinical case in which a patient observed by neurologists with a diagnosis of neuropathy and treated with anticonvulsants and antidepressants developed new clinical manifestations and laboratory changes characteristic of systemic lupus erythematosus. A clinical version emerged that the neurological changes were the disease onset, followed by the development of the remaining clinical and laboratory symptoms (the diagnosis fully met the 2019 EULAR criteria — a score of 16 points, 10 points are sufficient to make a diagnosis). However, after a very short and low-dose therapy with methylprednisolone and hydroxychloroquine and withdrawal of anticonvulsants, there was a rapid recovery of specific antibodies and improvement of clinical symptoms, which allowed assuming drug-induced lupus erythematosus in this patient. Currently, the list of drugs that can cause this problem includes more than 100 drugs.